BECN1 and breast carcinoma: Beclin 1 loss is associated with poor patient survival and more aggressive cancers [21] and mouse models harboring a single Beclin 1 copy have elevated incidence of spontaneous malignancies, including lung carcinomas, lymphomas, hepatocellular carcinomas and breast carcinomas [22,23,24].